trending Market Intelligence /marketintelligence/en/news-insights/trending/vh4u4jzkc0sdkvjvrly-wq2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

CytoDyn adds Argonne Capital president/CEO to board

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


CytoDyn adds Argonne Capital president/CEO to board

CytoDyn Inc. appointed Michael Klump to its board as a director.

Klump, who is also a significant CytoDyn investor, is the founder, president and CEO of private equity firm Argonne Capital Group LLC.

Vancouver, Wash.-based CytoDyn develops humanized monoclonal antibodies to treat and prevent HIV infection. Its lead drug candidate is PRO 140, a humanized immunoglobulin G4, or igG4, monoclonal antibody that blocks the cellular receptor implicated in HIV infection, tumor metastasis and immune signaling.